{"id":42989,"date":"2022-02-12T11:45:38","date_gmt":"2022-02-12T16:45:38","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=42989"},"modified":"2022-02-12T11:47:12","modified_gmt":"2022-02-12T16:47:12","slug":"infographic-cancer-drugs-main-pharma-money-source","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=42989","title":{"rendered":"Infographic – Cancer Drugs Main Pharma Money Source"},"content":{"rendered":"
\"Pharma<\/a>
Click on image for full-size view (Statista)<\/figcaption><\/figure>\n

12 Feb. 2022. In December, we ran a chart showing vaccines make up a small fraction<\/a> of overall drug sales worldwide, even Covid-19 vaccines. Our infographic this weekend broadens the issue to revenue sources overall for drug makers, and the leader by a wide margin is cancer drugs.<\/p>\n

The infographic’s data are compiled by business research company Statista in its Health Market Outlook<\/a>, a paid report, and displayed in a chart<\/a> earlier this month. Statista’s data show global cancer drug sales brought in $176 billion in 2021, 17 percent of total pharmaceutical industry revenues of $1.05 trillion. Vaccine sales totaled nearly $89 billion last year, with diabetes and rheumatic drugs for arthritis and other inflammatory conditions each selling $55 to $56 billion.<\/p>\n

By 2026, however, cancer drug sales are expected to grow to nearly $321 billion, making up 23 percent of all pharma revenues. Also by 2026, vaccine sales are projected to fall to $55 billion, but immunosuppressant drugs — biologics that limit the immune system — are expected to grow to $77 billion and take over second place. Pharma companies gained about $40 billion from anti-viral drugs in 2021, but that sales volume is not expected to grow much, reaching less than $44 billion in 2026.<\/p>\n

Statista compiled the data<\/a> from business, consumer, and government spending on pharmaceuticals, with projections based on models composed of financial, health care, and economic variables.<\/p>\n

More from Science & Enterprise:<\/p>\n